Morgan Stanley analyst Sean Laaman upgraded Exelixis (NASDAQ: EXEL) from Equalweight to Overweight and Assumed coverage with a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE